Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists under routine care.
接受常規護理的2型糖尿病患者中，使用SGLT2抑制劑或GLP-1受體激動劑的匹配隊列比較腎臟結果。
Diabetologia 2024-08-23
Parameters influencing renal response to SGLT2 inhibitors and GLP1 receptor agonists in type 2 diabetes patients with preserved renal function: a comparative, prospective study.
影響2型糖尿病患者腎功能保留時對SGLT2抑制劑和GLP1受體激動劑腎臟反應的參數：一項比較性前瞻性研究。
J Endocrinol Invest 2023-04-18
Comparative efficacy of sodium-glucose co-transporter-2 inhibitors, glucagon-like peptide-1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists in chronic kidney disease and type 2 diabetes: A systematic review and network meta-analysis.
慢性腎臟病和2型糖尿病中鈉葡萄糖共同轉運蛋白2抑製劑、葡萄糖樣肽-1受體激動劑和非類固醇礦質皮質激素受體拮抗劑的比較療效：系統性回顧和網絡荟萃分析。
Diabetes Obes Metab 2023-05-13
The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.
在接受胰高血糖素樣肽-1受體激動劑治療的日本2型糖尿病患者中，聯合使用鈉葡萄糖共同運輸蛋白2抑製劑改善了腎臟結果。
Cardiovasc Endocrinol Metab 2023-10-04
Renoprotective effects of combination treatment with sodium-glucose cotransporter inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus according to preceding medication.
糖尿病患者合併使用鈉葡萄糖共同轉運蛋白抑制劑和 GLP-1 受體激動劑的腎保護效應：根據先前用藥情況。
Diab Vasc Dis Res 2023-12-18
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes and mild/moderate chronic kidney disease.
第二型糖尿病患者合併輕至中度慢性腎臟疾病時，鈉葡萄糖共同轉運蛋白2抑制劑與葡萄糖樣肽-1受體激動劑的比較效果。
Diabetes Obes Metab 2024-03-14
Comparison of estimated glomerular filtration rate change with sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists among people with diabetes: A propensity-score matching study.
糖尿病患者中使用鈉葡萄糖共同轉運蛋白-2抑制劑與胰高血糖素樣肽-1受體激動劑對估計腎小球過濾率變化的比較：一項傾向性配對研究。
Diabetes Obes Metab 2024-03-26
Long-term comparison of renal and metabolic outcomes after sodium-glucose co-transporter 2 inhibitor or glucagon-like peptide-1 receptor agonist therapy in type 2 diabetes.
第二型糖尿病患者接受鈉葡萄糖共同轉運蛋白2抑製劑或葡萄糖樣肽-1受體激動劑治療後腎臟和代謝結果的長期比較。
BMC Med 2024-07-03
No Differences in Kidney Function Decline Between People With Type 2 Diabetes Starting a Sodium-Glucose Cotransporter 2 Inhibitor or a Glucagon-like Peptide-1 Receptor Agonist: A Real-world Retrospective Comparative Observational Study.
2型糖尿病患者開始使用鈉葡萄糖共同轉運蛋白2抑製劑或葡萄糖樣胰高血糖素受體激動劑之間的腎功能下降沒有差異：一項真實世界的回顧性比較觀察研究。
Clin Ther 2024-07-04
Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors vs GLP-1 Receptor Agonists in Type 2 Diabetes.
SGLT2 抑制劑與 GLP-1 受體激動劑在 2 型糖尿病中的腎臟與心血管效果比較。
J Am Coll Cardiol 2024-08-14